Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Stella Diagnostics, Inc., a molecular diagnostics-based company, focuses on enhancing patient management strategies for people living with severe esophageal diseases. Its clinical assays offer physicians insight into the molecular properties of patients' tissue to determine if the disease is stable, progressing, or turning cancerous. The company is also developing diagnostic tools that provides molecular information for providers as compared to the screening protocols. The company was formerly known as JMP Properties, Inc. and changed its name to Stella Diagnostics, Inc. in April 2021. Stella Diagnostics, Inc. is based in Salt Lake City, Utah.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is undervalued on P/FCF.
Buy
Sell